Newswire (Published: Thursday, December 19, 2019, 4:31:00 AM CST, Received: Thursday, December 19, 2019, 5:03:54 AM CST)
Word Count: 193
The FDA has approved
The approval allows the treatment to be used on patients with metastatic hormone-sensitive prostate cancer, which is a form of the disease that spreads to other parts of the body. 400,000 men live with this disease in the US.
The drug is the first oral treatment approved by the FDA to be used in treating three different types of advanced prostate cancer.
The drug had previously been approved for non-metastatic prostate cancer, a form of cancer which does not spread, and metastatic castration-resistant prostate cancer, which spread and grows despite hormone therapy.
Xtandi has already been prescribed to over 420,000 patients worldwide since it was first approved in 2012.
Prostate cancer is the most common cancer found in men. It is estimated that over 47,000 men are diagnosed with the disease every year, and more than 11,500 die from it every year.